Zoom-Based Mindfulness-Oriented Recovery Enhancement Plus Just-in-Time Mindfulness Practice Triggered by Wearable Sensors for Opioid Craving and Chronic Pain.

"Declarations Ethics ApprovalThe University of Utah provided IRB approval for the study. Informed ConsentParticipants gave written, informed consent to participate in this study. Conflict of InterestEric Garland, PhD, LCSW is the Director of the Center on Mindfulness and Integrative Health Intervention Development. The Center provides Mindfulness-Oriented Recovery Enhancement (MORE), mindfulness-based therapy, and cognitive behavioral therapy in the context of research trials for no cost to research participants; however, Dr. Garland has received payment for delivering lectures, and teaching engagements (related to training clinicians in mindfulness) sponsored by institutions of higher education, government agencies, and medical centers. Dr. Garland also receives royalties from the sale of books related to MORE. Dr. Garland is a licensor to BehaVR, LLC. Mark Tuomenoksa is the Chief Technology Officer of Illumivu. No other authors have any related conflicts of interest to disclose. DisclaimerThe funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Conflict of Interest Eric Garland, PhD, LCSW is the Director of the Center on Mindfulness and Integrative Health Intervention Development. The Center provides Mindfulness-Oriented Recovery Enhancement (MORE), mindfulness-based therapy, and cognitive behavioral therapy in the context of research trials for no cost to research participants; however, Dr. Garland has received payment for delivering lectures, and teaching engagements (related to training clinicians in mindfulness) sponsored by institutions of higher education, government agencies, and medical centers. Dr. Garland also receives royalties from the sale of books related to MORE. Dr. Garland is a licensor to BehaVR, LLC. Mark Tuomenoksa is the Chief Technology Officer of Illumivu. No other authors have any related conflicts of interest to disclose."

"Funding This research was supported by R01DA042033 (PI: Garland) and W81XWH-16–1-0522 (PI: Garland). ELG was also supported by R01AT011772 (PI: Garland), R01DA056537 (PI: Garland), and R01DA057631 (PI: Garland) during the preparation of this manuscript."

"Preregistration: This study is registered on ClinicalTrials.gov (NCT04567043)."